Qingyuan Zhang

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne et al. · Journal of Clinical Oncology · 2021 · 270 citations · Full text

Medicine, Hematology, Oncology +15

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 249 citations

Life Sciences, Immunology, Oncology +7

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Yuqin Song, Jianqiu Wu, Xinchuan Chen et al. · Clinical Cancer Research · 2019 · 157 citations

Medicine, Oncology, Pharmacology +17

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Matthew Ku, Mark P. Hertzberg, Huiqiang Huang et al. · The Lancet · 2024 · 142 citations

Medicine, Hematology, Oncology +15

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 137 citations · Full text

Medicine, Immunology, Pharmacology +11